Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Peregrine Pharmaceuticals Inc (NASDAQ:PPHM)

0.4002
Delayed Data
As of Dec 09
 +0.0773 / +23.94%
Today’s Change
0.29
Today|||52-Week Range
1.31
-65.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$97.0M

Company Description

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the provision of monoclonal antibody therapeutics. It operates through Peregrine and Avid segments. The Peregrine segment refers to research and development of monoclonal antibodies for the treatment and diagnosis of cancer. The Avid segment provides contract management services for peregrine and third-party customers on a fee-for-services basis. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Contact Information

Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin California 92780-7017
P:(714) 508-6000
Investor Relations:

Employees

Shareholders

Mutual fund holders4.38%
Other institutional19.66%
Individual stakeholders0.51%

Top Executives

Steven W. KingPresident, Chief Executive Officer & Director
Paul J. LytleCFO & Principal Accounting Officer
Joseph S. ShanVice President-Clinical & Regulatory Affairs
Mark R. ZiebellSecretary, Vice President & General Counsel
Shelley P. M. FusseyVice President-Intellectual Property